Disc Medicine Presents Pipeline Updates at ASH 2026
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Disc Medicine, Inc. announced it will present clinical updates at ASH 2026, highlighting the growing breadth of its portfolio. Presentations will include results from the RALLY-MF Phase 2 trial of selcodebart in anemia of myelofibrosis and the RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera. The company will also present initial data from a Phase 1b trial of DISC-3405 in sickle cell disease.
From manilatimes.net
Why it matters
The clinical updates reinforce the momentum across Disc Medicine, Inc.'s pipeline. Positive clinical information could reinforce analyst confidence and valuation outlook for Cantor Fitzgerald and Morgan Stanley.
From manilatimes.net
Who's involved
- J.D.John Quisel, J.D., Ph.D., President and Chief Executive Officer at Disc Medicine, Inc.